$ARTL News

Artelo Biosciences Announces Data From Preclinical Trial In Neuropathic Pain From Spinal Cord Injury Shows Lowered Mechanical Hypersensitivity Associated With Nerve Injury; Decreased Spontaneous Pain-Related Behaviors

Artelo Biosciences Identifies Lipid Pathway Link For ART26.12 In Multi-Omics Cancer Research Presentation At The CRS 2026 Annual Symposium

Artelo Biosciences Announces Two Presentations Supporting Development Of ART26.12, Its Selective Fatty Acid Binding Protein 5 Inhibitor

Artelo Biosciences Presents Metabolite Identification And Profiling Data From Its FABP Inhibitor Candidate ART26.12; Tracks Three Metabolites From Plasma Of Healthy Volunteers Given Single 900 Mg Oral Dose Of ART26.12

Artelo Biosciences Files Prospectus To Offer Up To $6.53M In Common Stock Via H.C. Wainwright

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

Artelo Biosciences Q1 EPS $(4.00) Misses $(1.57) Estimate

Artelo Biosciences Files Prospectus For Offering $75M Mixed Shelf

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

Artelo Biosciences Collaborates With ScienceMachine Over Development Of Its Fatty Acid-Binding Protein 5 Inhibitor Platform

What's Behind The Rise In Artelo Biosciences Stock?

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Artelo shares are trading higher after the company announced the publication of a peer‑reviewed article titled "Evaluating fatty acid-binding protein 5 (FABP5) as a therapeutic target for pain management" in the European Journal of Pain.

Artelo shares are trading higher after the company announced the publication of a peer‑reviewed article titled "Evaluating fatty acid-binding protein 5 (FABP5) as a therapeutic target for pain management" in the European Journal of Pain.

Artelo Biosciences Announces Publication Of Peer‑Reviewed Article On FABP5 As Therapeutic Target For Pain Management In European Journal Of Pain

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

ARTL stock has given up its prior gain. Artelo Biosciences shares were trading higher after the company announced it regained Nasdaq compliance.

Artelo Biosciences shares are trading higher after the company announced it regained Nasdaq compliance.

Artelo Biosciences Regains Nasdaq Compliance

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules